138 related articles for article (PubMed ID: 26803521)
1. TLR4 signaling mediates AP-1 activation in an MPTP-induced mouse model of Parkinson's disease.
Zhao XD; Wang FX; Cao WF; Zhang YH; Li Y
Int Immunopharmacol; 2016 Mar; 32():96-102. PubMed ID: 26803521
[TBL] [Abstract][Full Text] [Related]
2. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Shao QH; Chen Y; Li FF; Wang S; Zhang XL; Yuan YH; Chen NH
Acta Pharmacol Sin; 2019 Dec; 40(12):1503-1512. PubMed ID: 31388087
[TBL] [Abstract][Full Text] [Related]
3. [Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway].
Wang Q; Zheng H; Zhang ZF; Zhang YX
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1594-8. PubMed ID: 18819875
[TBL] [Abstract][Full Text] [Related]
4. [Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
Wang YS; Zhou JP; Wei ZF; Tian QY; Zhou HX; Zhang YX
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1199-202, 1205. PubMed ID: 17715026
[TBL] [Abstract][Full Text] [Related]
5. [Resveratrol protects dopaminergic neurons in a mouse model of Parkinson's disease by regulating the gut-brain axis
Gui J; Sun X; Wen S; Liu X; Qin B; Sang M
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):270-279. PubMed ID: 38501412
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.
Zhang J; Sun B; Yang J; Chen Z; Li Z; Zhang N; Li H; Shen L
Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35039876
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice.
Hwang CJ; Choi DY; Jung YY; Lee YJ; Yun JS; Oh KW; Han SB; Oh S; Park MH; Hong JT
Horm Behav; 2016 Apr; 80():19-29. PubMed ID: 26836768
[TBL] [Abstract][Full Text] [Related]
8. A role for glia maturation factor dependent activation of mast cells and microglia in MPTP induced dopamine loss and behavioural deficits in mice.
Selvakumar GP; Ahmed ME; Thangavel R; Kempuraj D; Dubova I; Raikwar SP; Zaheer S; Iyer SS; Zaheer A
Brain Behav Immun; 2020 Jul; 87():429-443. PubMed ID: 31982500
[TBL] [Abstract][Full Text] [Related]
9. Artemisinin exerts a protective effect in the MPTP mouse model of Parkinson's disease by inhibiting microglial activation via the TLR4/Myd88/NF-KB pathway.
Lv J; Zhu J; Wang P; Liu T; Yuan J; Yin H; Lan Y; Sun Q; Zhang Z; Ding G; Zhou C; Wang H; Wang Z; Wang Y
CNS Neurosci Ther; 2023 Apr; 29(4):1012-1023. PubMed ID: 36691817
[TBL] [Abstract][Full Text] [Related]
10. Toll Like Receptor 4 Affects the Cerebral Biochemical Changes Induced by MPTP Treatment.
Conte C; Roscini L; Sardella R; Mariucci G; Scorzoni S; Beccari T; Corte L
Neurochem Res; 2017 Feb; 42(2):493-500. PubMed ID: 28108849
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Kanagaraj N; Beiping H; Dheen ST; Tay SS
Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
[TBL] [Abstract][Full Text] [Related]
12. TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model.
Campolo M; Paterniti I; Siracusa R; Filippone A; Esposito E; Cuzzocrea S
Brain Behav Immun; 2019 Feb; 76():236-247. PubMed ID: 30550933
[TBL] [Abstract][Full Text] [Related]
13. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
14. The Potential Role of Toll-Like Receptor 4 in Mediating Dopaminergic Cell Loss and Alpha-Synuclein Expression in the Acute MPTP Mouse Model of Parkinson's Disease.
Mariucci G; Pagiotti R; Galli F; Romani L; Conte C
J Mol Neurosci; 2018 Apr; 64(4):611-618. PubMed ID: 29589201
[TBL] [Abstract][Full Text] [Related]
15. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells.
Otto D; Unsicker K
Glia; 1994 May; 11(1):47-56. PubMed ID: 8070894
[TBL] [Abstract][Full Text] [Related]
16. [Effect of phosphorylated-ERK1/2 on inducible nitric oxide synthase expression in the substantia nigra of mice with MPTP-induced Parkinson disease].
Shi C; Zhang YX; Zhang ZF
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan; 29(1):60-3. PubMed ID: 19218114
[TBL] [Abstract][Full Text] [Related]
17. [Protective effects of Cistanche total glycosides on dopaminergic neuron in substantia nigra of model mice of Parkinson's disease].
Li WW; Yang R; Cai DF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Mar; 28(3):248-51. PubMed ID: 18476428
[TBL] [Abstract][Full Text] [Related]
18. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
Aoki E; Yano R; Yokoyama H; Kato H; Araki T
Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice.
Cheng YY; Chen BY; Bian GL; Ding YX; Chen LW
Mol Neurobiol; 2022 Apr; 59(4):2642-2655. PubMed ID: 35142987
[TBL] [Abstract][Full Text] [Related]
20. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
